MedTrace Logo

Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection

NCT07709299 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-07-16

No results posted yet for this study

Summary

This study tests whether it is safe and feasible to give patients with hepatocellular carcinoma (liver cancer) an infusion of their own (autologous) immune cells, called cytokine-induced killer (CIK) cells, after they have had surgery to remove their liver tumor. The patient's own blood cells are collected and grown in a laboratory to create the CIK cells, which are then given back to the patient through six intravenous infusions over about two months. Patients are followed for six months to check for side effects and early signs of whether the cancer returns.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

BIOLOGICAL

Autologous Cytokine-Induced Killer (CIK) Cells

PBMCs are collected from the patient, expanded ex vivo for 14-21 days under GMP conditions administered as 6 intravenous infusions (weeks 0, 1, 2, then weeks 4, 6, 8) following release testing for sterility, viability, and phenotype.

Sponsors & Collaborators

  • Bahar Tashkhis Teb

    collaborator UNKNOWN

  • Kian Immune Cell Company

    collaborator INDUSTRY

  • Royan Institute

    lead OTHER_GOV

Principal Investigators

  • Massoud Vosough, MD, Ph.D. · Royan Institute

  • Mohsen Nassiri-Toosi, MD · Liver Transplant Research Center, Tehran University of Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2028-07-31
Completion
2028-07-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07709299 on ClinicalTrials.gov